

STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT

Docket No.

2290.00061

7-15  
1-200  
a/achan

In Re Application Of: Sara Lavi

Serial No.  
09/029,479

Filing Date  
10/21/98

Examiner  
Woitach, J.

Group Art Unit  
1632

Invention:

**MANIPULATION AND DETECTION OF PROTEIN PHOSPHATASE 2C-PP2Ca-EXPRESSION IN TUMOR  
CELLS FOR CANCER DETECTION AND THERAPY**

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.


Check applicable statement herebelow:

Statement Under 37 CFR 1.97(e)(1)

Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Statement Under 37 CFR 1.97(e)(2)

No item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement.

  
Signature

Dated: July 5, 2001

Amy E. Rinaldo, Reg. No. 45,791  
Kohn & Associates  
30500 Northwestern Highway, Suite 410  
Farmington Hills, Michigan 48334  
(248) 539-5050


I certify that this document is being deposited on  
7/5/01 with the U.S. Postal Service as first  
class mail under 37 C.F.R. 1.8 and is addressed to the  
Assistant Commissioner for Patents, Washington, D.C.  
20231.

  
Signature of Person Mailing Correspondence

cc:

Connie Herty

Typed or Printed Name of Person Mailing Correspondence



## MANUAL OF PATENT EXAMINING PROCEDURE

PTO/SB/08 (2-92)

Sheet 1 of 1

Form PTO-1449  
**S U P P L E M E N T A L**  
INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)  
2290.00061Application Number  
09/029,479Applicant  
Sara LaviFiling Date  
10/21/98Group Art Unit  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

	Fukushige S, Sauer B. "Genomic targeting with a positive-selection lox integration vector allows highly reproducible gene expression in mammalian cells. Proc Natl Acad Sci USA 1992 Sep 1;89 (17):7905-9.
	Gage PJ et al. "A cell-free recombination system for site-specific integration of multigenic shuttle plasmids into the herpes simplex virus type 1 genome. J. Virol 1992 Sep; 66 (9):5509-15.
	Holt CL and May GS. "A novel phage lambda replacement Cre-lox vector that has automatic subcloning capabilities." Gene. 1993 Oct 29;133 (1):95-7.

EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.